“Our goal is to meet patients where they are in their health journey,” said Anthony Alvarez, SVP and GM of Edgepark. “Diabetes is one of the fastest-growing conditions in the United States, and the introduction of innovations like a one-year wearable system and blood glucose biosensors that can be used without a prescription will no doubt play a pivotal role in the well-being of the patients we serve.”

Updates to the Edgepark diabetes product portfolio

Biosensor technology: Dexcom Stelo Glucose Biosensor™ System (Stelo)

The first-ever FDA-cleared over-the-counter glucose biosensor, the Dexcom Stelo, is now available through Edgepark, one of the limited number of suppliers to offer it. This biosensor represents a significant leap in glucose monitoring by expanding access to this technology for adults not on insulin and who don’t have a history of problematic hypoglycemia. Its groundbreaking accessibility, coupled with the ability to provide glucose insights directly to a smartphone without fingersticks, empowers a wider population to proactively understand and manage their metabolic health. This product is FSA/HSA eligible and can be ordered without a prescription from a healthcare provider here.